Focus: Vera Therapeutics is a public biotech company focused on gene editing and gene therapy, operating at mid-cap scale with 51-200 employees. The company maintains an active clinical pipeline spanning immunology, infectious disease, and oncology indications.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Stable — net +1 jobs in 30d
7 added, 6 removed. Backfill posture.
High-risk opportunity suitable only for early-stage biotech professionals willing to bet on pipeline catalysts within 18-24 months; due diligence on Atacicept Phase 3 data quality and cash burn trajectory is essential.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Vera Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Vera Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo